Johnson & Johnson Executive Vice President and Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., will be hanging up his hat this September.
Hait’s planned retirement comes after a 17-year run with the healthcare giant, starting back in 2007 when he joined J&J’s Janssen arm as senior vice president and therapeutic area head of hematology and oncology.
From 2011 to 2018, Hait served as global head of innovative medicine R&D, taking up the role again as interim head between 2022 and 2023. Under his leadership, the pharma’s innovative medicine unit launched more than 20 new products, including BTK blocker Imbruvica (ibrutinib), monoclonal antibody Tremfya (guselkumab) and hormone therapy drug Zytiga (abiraterone acetate), according to a company release.
Before J&J, Hait was the founding director of the Rutgers Cancer Institute of New Jersey, the state’s first and only National Cancer Institute-designated comprehensive cancer center.